Navigation Links
Defective cell surface 'glue' is key to tumor invasion
Date:12/13/2010

This release is available in French.

A remarkable discovery into how tumour cells invade normal tissue should lead to vital diagnostic tools and help develop strategies to stop the spread of cancer cells. A new study by scientists at the Montreal Neurological Institute and Hospital of McGill University reveals that the surface of aggressive tumour cells lack the strong molecular 'glue' responsible for binding normal cells together. This allows tumour cells to break away, detach from their neighbors, and spread to other regions of the body.

Certain proteins, called cadherins, are located on the surface of cells and play a vital role in cell adhesion or 'gluing' cells together, ensuring the proper organization of tissue. What happens to the cells and the 'glue' that binds them in tumour growth and metastases is poorly understood. "We were concerned that previous research showed that N-cadherin, an adhesive molecule, was important for both normal tissue organization, as well as tumour metastasis," says Dr. David Colman, Director of The Neuro and corresponding author of the study. "We therefore decided to further investigate this apparent paradox."

The team studied the levels of N-cadherin on tumour cell surfaces. "Our study shows that a non-adhesive form of N-cadherin, termed proNcad is present in a much higher proportion on the surfaces of the most invasive melanoma, brain tumour cells, breast cancer and prostate tumour cells, compared to less invasive tumour cells." says Dr. Deborah Maret, research associate and lead author. This non-adhesive form of N-cadherin never reaches the cell surface in normal tissues.

"It appears that although total N-cadherin levels remain constant, the higher levels of the non-adhesive proNcad promote detachment, tumor cell migration and invasion," adds Dr. Maret. "This supports an overall conclusion that non-adhesive (proNcad) and adhesive (Ncad) forms of cadherins co-exist on tumour cell surfaces, but it is the ratio between these functionally opposite molecules that directly dictates the invasion potential of tumour cells." Because the differences between the two forms of cadherin are so small, previous studies have missed detecting the non-adhesive proNcad form on tumour cell surfaces. Hence it was assumed that all Ncad on the tumour cell surface was of the adhesive type. "We were astounded that this was not the case at all," says Dr. Colman.

"As a brain tumour surgeon, I know that stopping cancer cells from migrating is critical for patient survival," says Dr. Rolando Del Maestro, Director of The Brain Tumour Research Centre and a co-author on the study. "We are determined to improve treatment options for patients. We have already introduced new neurosurgical methods and technologies that are unique in North America and are spearheading multidisciplinary initiatives to advance brain tumour research."

Determining the ratios of Ncad and proNcad on the cell surface may serve as a tremendously valuable tool for the staging and progression of malignant tumors. The findings may also shed light on new treatment strategies to arrest the metastatic spread of invasive tumor cells.


'/>"/>

Contact: Anita Kar
anita.kar@mcgill.ca
514-398-3376
McGill University
Source:Eurekalert

Related biology news :

1. Defective protein is a double hit for ataxia
2. Research project yields better understanding of the defective protein that causes cystic fibrosis
3. Would a molecular horse trot, pace or glide across a surface?
4. LSUs WAVCIS director says oil remains below surface, will come ashore in pulses
5. Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells
6. Fly eye paves the way for manufacturing biomimetic surfaces
7. New model is proposed to explain absence of organic compounds on surface of Mars
8. Invasive kudzu is major factor in surface ozone pollution, study shows
9. Helping the NRC look below the surface
10. 40 percent of surface disinfectants ineffective in eliminating viruses that cause gastroenteritis
11. Water may not run uphill, but it practically flies off new surface
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, a ... emerging technology, announces the availability of a new report, Sensors ... Continue Reading ... ... and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... 27, 2017 Four US Biotech ... today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), ... Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... Trends, market observers are growing more bullish on the ... reforms to free cash held overseas for tax reason ...
(Date:2/27/2017)... , ... February 27, 2017 , ... The Catalyst ... a few in the Midwest offering premix services and private label organic services. , ... laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, which owns the ...
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
Breaking Biology Technology: